Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUME-Meso: Nintedanib in Unresectable Malignant Pleural Mesothelioma
NCT01907100Phase 3Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2013
- Primary completion
- Mar 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial in malignant pleural mesothelioma (MPM) comparing Nintedanib Arm with Placebo Arm (2 arms). Primary endpoint: Progression-Free Survival at 31 months. Started Sep 2013; status: terminated.
02
Drugs
nintedanib
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT01907100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01907100.